13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • XL184-313

    Acronym: 

    XL184-313

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Other
    Trial Type Treatment
    Phase Phase III Tumour Stream RCC
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Other
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream RCC
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A randomised, double-blind, controlled phase III study of cabozantinib in combination with nivolumab and ipilimumab vs. nivolumab in previously untreated advanced or metastatic RCC of intermediate or poor risk.

    Lay Summary

    Sponsor / Cooperative group

    Medpace/ Exelixis

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Not Yet Recruiting